Share Search
Visit the Share Search
You are here:
Silence Therapeutics taps Craig Tooman for CFO
6th Jan 2021 08:06
(Sharecast News) - Drug discovery outfit Silence Therapeutics has named Craig Tooman as its new chief financial officer.
Silence said on Wednesday that Tooman, previously of Vyome Therapeutics, will take on the role and join the group's executive leadership team with immediate effect.
Chief executive Mark Rothera said: "Craig brings a deep understanding of financial strategy, US capital markets and business development to Silence.
"His appointment comes at a time of significant opportunity and growth, highlighted by the advancement of our two wholly-owned product candidates into the clinic and three anticipated clinical data readouts this year. His business and financial expertise will be instrumental in helping us build our US footprint and positioning Silence as a leading global RNAi business."
As of 1135 GMT, Silence shares were up 1.56% at 534.20p.
Silence said on Wednesday that Tooman, previously of Vyome Therapeutics, will take on the role and join the group's executive leadership team with immediate effect.
Chief executive Mark Rothera said: "Craig brings a deep understanding of financial strategy, US capital markets and business development to Silence.
"His appointment comes at a time of significant opportunity and growth, highlighted by the advancement of our two wholly-owned product candidates into the clinic and three anticipated clinical data readouts this year. His business and financial expertise will be instrumental in helping us build our US footprint and positioning Silence as a leading global RNAi business."
As of 1135 GMT, Silence shares were up 1.56% at 534.20p.